{"id":"f9784f2f8e56","type":"article","url":"https://hartvaat.nl/2019/09/01/remote-monitoring-en-patientgerapporteerde-uitkomsten-bij-europese-hf-patienten-/","title":"Remote monitoring en patiëntgerapporteerde uitkomsten bij Europese HF-patiënten met ICD","title_en":"Effect of remote monitoring on patient-reported outcomes in European heart failure patients with an implantable cardioverter-defibrillator: primary results of the REMOTE-CIED randomized trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euz140","source_url":"https://doi.org/10.1093/europace/euz140","authors":["Henneke Versteeg","Ivy Timmermans","Jos Widdershoven","Geert-Jan Kimman","Sébastien Prevot","Thomas Rauwolf","Marcoen F Scholten","Edgar Zitron","Philippe Mabo","Johan Denollet","Susanne S Pedersen","Mathias Meine"],"significance":5,"published":"2019-09-01","source_date":"2019-09-01","image":"","kennis":[],"congress":"","summary_en":"This European REMOTE-CIED study was the first randomized trial designed to evaluate the effect of remote patient monitoring on patient-reported outcomes in heart failure patients with ICDs, addressing the patient-centered value of telemonitoring.","created":"2026-07-03T10:28:07Z","updated":"2026-07-03T13:27:19Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie naar het effect van remote monitoring op patiëntgerapporteerde uitkomsten bij Europese hartfalenpatiënten met een ICD.","abstract_original":"AIMS: The European REMOTE-CIED study is the first randomized trial primarily designed to evaluate the effect of remote patient monitoring (RPM) on patient-reported outcomes in the first 2 years after implantation of an implantable cardioverter-defibrillator (ICD). METHODS AND RESULTS: The sample consisted of 595 European heart failure patients implanted with an ICD compatible with the Boston Scientific LATITUDE® RPM system. Patients were randomized to RPM plus a yearly in-clinic ICD check-up vs. 3-6-month in-clinic check-ups alone. At five points during the 2-year follow-up, patients completed questionnaires including the Kansas City Cardiomyopathy Questionnaire and Florida Patient Acceptance Survey (FPAS) to assess their heart failure-specific health status and ICD acceptance, respectively. Information on clinical status was obtained from patients' medical records. Linear regression models were used to compare scores between groups over time. Intention-to-treat and per-protocol analyses showed no significant group differences in patients' health status and ICD acceptance (subscale) scores (all Ps > 0.05). Exploratory subgroup analyses indicated a temporary improvement in device acceptance (FPAS total score) at 6-month follow-up for secondary prophylactic in-clinic patients only (P < 0.001). No other significant subgroup differences were observed. CONCLUSION: Large clinical trials have indicated that RPM can safely and effectively replace most in-clinic check-ups of ICD patients. The REMOTE-CIED trial results show that patient-reported health status and ICD acceptance do not differ between patients on RPM and patients receiving in-clinic check-ups alone in the first 2 years after ICD implantation.ClinicalTrials.gov Identifier: NCT01691586."}